Volume 16, Number 11—November 2010
Estimates of the True Number of Cases of Pandemic (H1N1) 2009, Beijing, China
During 2009, a total of 10,844 laboratory-confirmed cases of pandemic (H1N1) 2009 were reported in Beijing, People’s Republic of China. However, because most cases were not confirmed through laboratory testing, the true number is unknown. Using a multiplier model, we estimated that ≈1.46–2.30 million pandemic (H1N1) 2009 infections occurred.
Infection with a novel swine-origin influenza A (H1N1) virus, currently named pandemic (H1N1) 2009 virus, first occurred in the United States and Mexico in early April 2009 (1,2) and then rapidly spread to other regions of the world. As the outbreak expanded, laboratory testing of persons with suspected cases became increasingly impractical, extremely resource intensive, and was discontinued. We assume, therefore, that the number of laboratory-confirmed cases represents only a small fraction of the actual number of infections (3–5). In this study, we used a multiplier model to estimate the true number of cases of pandemic (H1N1) 2009 in Beijing, People’s Republic of China.
To estimate the prevalence of pandemic (H1N1) 2009 in the United States, the US Centers for Disease Control and Prevention (CDC) developed a software program (Impact2009, version 1.0) (6) based on the Monte Carlo approach and the multiplier model. Although this simple and useful program can be used to estimate the true number of cases in the United States, it may not be so readily applied to other countries because of uncertainties in the model parameters. To account for these uncertainties, in this study we decided to alter the way in which the baseline data assumptions were calculated. For example in the original CDC model, the prevalence was calculated on the basis of the laboratory-confirmed case data. In contrast, we calculated the baseline case number by multiplying the reported number of influenza-like illness (ILI) cases in secondary and tertiary hospitals by the positive rate of pandemic (H1N1) 2009 among ILI cases. We obtained this information from the Beijing influenza surveillance system, which encompasses data on ILI cases from all secondary and tertiary hospitals (levels 2, 3), and virologic surveillance data (7).
From the virologic surveillance data, we determined that positive cases of pandemic (H1N1) 2009 were identified through August 3, 2009. From this finding, we used 2 phases for the model: phase 1 (May 16, 2009, through August 2, 2009) and phase 2 (August 3, 2009 through December 31, 2009). In addition, the consultation rate for ILI cases had changed over the course of the pandemic, because of changes in strategies used to control the disease in Beijing before and after National Day (October 1). To adjust for the introduction of these strategies, we further divided phase 2 into 2 periods: period 2a (from August 3, 2009, through September 30, 2009) and period 2b (from October 1, 2009, through December 31, 2009).
During phase 1, the number of laboratory-confirmed cases was considered to reflect the true number of pandemic (H1N1) 2009 infections. However, during phase 2, we calculated the true number of infections by multiplying the baseline by the estimation coefficient, using the multiplier model. In this multiplier model, the baseline case number was equal to the sum of the product of the weekly ILI case number in level 2 and 3 hospitals and the corresponding weekly pandemic (H1N1) 2009 positive rate among case-patients with ILIs. The estimation coefficient was found by multiplying the reciprocal of the parameters in the model. The following parameters were required in our estimation: the proportion of symptomatic infection among patients with cases of pandemic (H1N1) 2009, the proportion of ILI among patients with symptomatic cases of pandemic (H1N1) 2009, the consultation rate among ILI case-patients, the sampling success rate, and the sensitivity of the test (Figure; Table 1). These terms were obtained from a review of the literature (8–12) and from recommendations by health professionals. We assumed that the consultation rate of ILIs in each of the 2 periods was consistent and that the syndromic profile of pandemic (H1N1) 2009 did not change greatly.
In phase 1, a total of 325 positive cases were reported (considered as the true infection number). In period 2a and period 2b of phase 2, the baseline case numbers were 6,520 and 171,899, respectively. During phase 2, a total of 1,800,074 pandemic (H1N1) 2009 infections were estimated. Thus, by the end of 2009, the cumulative number of persons infected with pandemic (H1N1) 2009 in Beijing was estimated to be 1,800,399 (90% range 1.46–2.30 million) (Table 2). However, only 10,844 laboratory-confirmed cases were reported during the same period. One laboratory-confirmed case equaled 166 (90% range 135–212) infections in reality. According to the population size of Beijing, the overall infection rate was 10.6%. The highest infection rate was recorded in those 5–14 years of age (31.8%), followed by those 0–4 years of age (30.8%) (Table 2). In comparison, the rate in persons >60 years was only 0.9%.
Despite the small number of laboratory-confirmed cases (10,844), we estimated that the actual number of persons infected with pandemic (H1N1) 2009 was 1.8 million in Beijing by the end of 2009. Previous studies have claimed that the number of laboratory-confirmed cases of pandemic (H1N1) 2009 was substantially underestimated, reflecting only a very small fraction of the actual infections (3–5). This study also demonstrated that school age children were more likely to be infected with pandemic (H1N1) 2009. However, those >60 years of age were at low risk for infection.
From November 27 through December 7, 2009, a serologic survey to establish the prevalence of pandemic (H1N1) 2009 antibody was conducted in the general population of Beijing. The results showed that ≈14%–15% (13) of the general population had antibodies to pandemic (H1N1) 2009 virus. Based on the population size of 17 million in Beijing in 2009 (14) and the assumption that antibodies against pandemic (H1N1) 2009 virus are usually produced after 2 weeks of infection or vaccination, we estimated that 2.37 to 2.54 million persons were infected with pandemic (H1N1) 2009 virus as of November 13, 2009. According to data from the Beijing Center for Disease Prevention and Control, by November 13, 2009, 1.36 million persons had received the pandemic (H1N1) 2009 vaccine. After the vaccinated population were removed from the equation, the total number of pandemic (H1N1) 2009 cases was estimated to be ≈1.01 to1.18 million. At the same time, the number of infections was estimated at 0.87–1.28 million as of November 13, 2009, by the multiplier model (data not shown in the section of the study). The estimates of the infection matched with the actual number estimated from the serologic survey in principle.
In phase 1, the number of laboratory-confirmed cases was considered to reflect the true infection number. This assumption, however, may lead to an underestimation for 2 reasons. First, we ignored the parameters used in phase 2, and second, difficulties occurred in testing all of the samples taken from patients who sought consultation for ILIs. Nevertheless, because the pandemic did not spread in the community in phase 1, we believe that this underestimation would have been quite low.
Although, in theory, serologic surveys should provide an accurate record of the infection rate of pandemic (H1N1) 2009, they failed to provide a quicker and more representative result than the multiplier model. Given the similarities between the estimates obtained from the model and the estimates obtained from the serologic survey, we conclude that the multiplier model based on the Monte Carlo approach should be considered a useful and simple method for estimating the true number of infections during a pandemic.
Dr Xiaoli Wang is a medical epidemiologist at the Institute for Infectious Disease and Endemic Disease Control of Beijing Center for Disease Prevention and Control. Her research interests are the epidemiology of respiratory infectious diseases and early-warning surveillance systems for emerging infections.
This study was funded by Beijing Natural Science Foundation (7082047), National 863 Project (2008AA02Z416), National Sci-Tech Key Projects During the Eleventh Five-Year Plan Period (2009ZX10004-315), and Key Task Of Novel H1N1 Flu Prevention Strategy of Beijing Sci-Tech Bureau (Z09050700940905).
- Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, Hernandez M, Quinones-Falconi F, Bautista E, Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med. 2009;361:680–9.
- Centers for Disease Control and Prevention. Swine influenza A (H1N1) infection in two children—southern California, March–April 2009. MMWR Morb Mortal Wkly Rep. 2009;58:400–2.
- Garske T, Legrand J, Donnelly CA, Ward H, Cauchemez S, Fraser C, Assessing the severity of the novel influenza A/H1N1 pandemic. BMJ. 2009;339:b2840.
- Lipsitch M, Lajous M, O’Hagan JJ, Cohen T, Miller JC, Goldstein E, Use of cumulative incidence of novel influenza A/H1N1 in foreign travelers to estimate lower bounds on cumulative incidence in Mexico. PLoS ONE. 2009;4:e6895.
- Colizza V, Vespignani A, Perra N, Poletto C, Goncalves B, Hu H, Estimate of novel influenza A/H1N1 cases in Mexico at the early stage of the pandemic with a spatially structured epidemic model. PLoS Currents. 2009:RRN1129.6.
- Yang P, Duan W, Lv M, Shi W, Peng X, Wang X, Review of an influenza surveillance system, Beijing, People’s Republic of China. Emerg Infect Dis. 2009;15:1603–8.
- Reed C, Angulo FJ, Swerdlow DL, Lipsitch M, Meltzer MI, Jernigan D, Estimates of the prevalence of pandemic (H1N1) 2009, United States, April–July 2009. Emerg Infect Dis. 2009;15:2004–7.
- Centers for Disease Control and Prevention. CDC estimates of 2009 H1N1 influenza cases, hospitalizations, and deaths in the United States. April–October 17, 2009 [cited 2009 Nov 27]. http://www.cdc.gov/h1n1flu/estimates_2009_h1n1.htm
- Li YP, Qian Q, Fang LQ, Yang H, Wei MT, Gao Y, Epidemiological characteristics of 420 influenza A (H1N1) cases confirmed in the early stage of the epidemic in mainland China [in Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi. 2009;30:1102–5.
- Yan J, Wang YG, Xiao J, Zhang SJ, Chen ZH, Guo LM, A clinical analysis of 33 cases of H1N1 influenza A [in Chinese]. Zhonghua Nei Ke Za Zhi. 2009;48:830–2.
- European Centre for Disease Prevention and Control. ECDC risk assessment. Pandemic H1N1 2009, version 6, 6 Nov 2009 [cited 2009 Nov 7]. http://ecdc.europa.eu/en/healthtopics/H1N1/Documents/1001_RA_091106.pdf
- Director of Beijing Health Bureau. Novel H1N1 flu epidemic decreased, the cumulative severe cases were 541. Annual Pharmacology Conference, 2009 [cited 2009 Nov 7]. http://www.cnr.cn/gundong/200912/t20091219_505781707.html
- Beijing Economic Information Center. Permanent population in Beijing reached 16.95 million [cited 2009 Nov 7]. http://www.beinet.net.cn/jjyw/shfz/200901/t320179.htm
- World Health Organization. Use of the pandemic (H1N1) 2009 vaccines, October 30, 2009 [cited 2009 Oct 30]. http://www.who.int/csr/disease/swineflu/frequently_asked_questions/vaccine_preparedness/use/en/index.html
Suggested citation for this article: Wang X, Yang P, Seale H, Zhang Y, Deng Y, Pang X, et al. Estimates of the true number of cases of pandemic (H1N1) 2009, Beijing, China. Emerg Infect Dis [serial on the Internet]. 2010 Nov [date cited]. http://wwwnc.cdc.gov/eid/article/16/11/10-0323
- Page created: March 03, 2011
- Page last updated: March 03, 2011
- Page last reviewed: March 03, 2011
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)